Show simple item record

dc.contributor.authorDuell, Eric J
dc.contributor.authorLujan-Barroso, Leila
dc.contributor.authorSala, Núria
dc.contributor.authorDeitz McElyea, Samantha
dc.contributor.authorOvervad, Kim
dc.contributor.authorTjonneland, Anne
dc.contributor.authorOlsen, Anja
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorBusund, Lill-Tove
dc.contributor.authorMoi, Line
dc.contributor.authorMuller, David
dc.contributor.authorVineis, Paolo
dc.contributor.authorAune, Dagfinn
dc.contributor.authorMatullo, Giuseppe
dc.contributor.authorNaccarati, Alessio
dc.contributor.authorPanico, Salvatore
dc.contributor.authorTagliabue, Giovanna
dc.contributor.authorTumino, Rosario
dc.contributor.authorPalli, Domenico
dc.contributor.authorKaaks, Rudolf
dc.contributor.authorKatzke, Verena A
dc.contributor.authorBoeing, Heiner
dc.contributor.authorBueno-de-Mesquita, H B As
dc.contributor.authorPeeters, Petra H
dc.contributor.authorTrichopoulou, Antonia
dc.contributor.authorLagiou, Pagona
dc.contributor.authorKotanidou, Anastasia
dc.contributor.authorTravis, Ruth C
dc.contributor.authorWareham, Nick
dc.contributor.authorKhaw, Kay-Tee
dc.contributor.authorRamon Quiros, Jose
dc.contributor.authorRodríguez-Barranco, Miguel
dc.contributor.authorDorronsoro, Miren
dc.contributor.authorChirlaque, María-Dolores
dc.contributor.authorArdanaz, Eva
dc.contributor.authorSeveri, Gianluca
dc.contributor.authorBoutron-Ruault, Marie-Christine
dc.contributor.authorRebours, Vinciane
dc.contributor.authorBrennan, Paul
dc.contributor.authorGunter, Marc
dc.contributor.authorScelo, Ghislaine
dc.contributor.authorCote, Greg
dc.contributor.authorSherman, Stuart
dc.contributor.authorKorc, Murray
dc.date.accessioned2018-02-06T13:10:11Z
dc.date.available2018-02-06T13:10:11Z
dc.date.issued2017-09-01
dc.identifier.citationPlasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. 2017, 141 (5):905-915 Int. J. Canceren
dc.identifier.issn1097-0215
dc.identifier.pmid28542740
dc.identifier.doi10.1002/ijc.30790
dc.identifier.urihttp://hdl.handle.net/10029/621305
dc.description.abstractNoninvasive biomarkers for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and disease risk stratification are greatly needed. We conducted a nested case-control study within the Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate prediagnostic microRNAs (miRs) as biomarkers of subsequent PDAC risk. A panel of eight miRs (miR-10a, -10b, -21-3p, -21-5p, -30c, -106b, -155 and -212) based on previous evidence from our group was evaluated in 225 microscopically confirmed PDAC cases and 225 controls matched on center, sex, fasting status and age/date/time of blood collection. MiR levels in prediagnostic plasma samples were determined by quantitative RT-PCR. Logistic regression was used to model levels and PDAC risk, adjusting for covariates and to estimate area under the receiver operating characteristic curves (AUC). Plasma miR-10b, -21-5p, -30c and -106b levels were significantly higher in cases diagnosed within 2 years of blood collection compared to matched controls (all p-values <0.04). Based on adjusted logistic regression models, levels for six miRs (miR-10a, -10b, -21-5p, -30c, -155 and -212) overall, and for four miRs (-10a, -10b, -21-5p and -30c) at shorter follow-up time between blood collection and diagnosis (≤5 yr, ≤2 yr), were statistically significantly associated with risk. A score based on the panel showed a linear dose-response trend with risk (p-value = 0.0006). For shorter follow-up (≤5 yr), AUC for the score was 0.73, and for individual miRs ranged from 0.73 (miR-212) to 0.79 (miR-21-5p).
dc.language.isoenen
dc.rightsinfo:eu-repo/semantics/closedAccessen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshArea Under Curve
dc.subject.meshBiomarkers, Tumor
dc.subject.meshCarcinoma, Pancreatic Ductal
dc.subject.meshCase-Control Studies
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMicroRNAs
dc.subject.meshMiddle Aged
dc.subject.meshPancreatic Neoplasms
dc.subject.meshPolymerase Chain Reaction
dc.subject.meshProspective Studies
dc.subject.meshROC Curve
dc.subject.meshSensitivity and Specificity
dc.titlePlasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.en
dc.typeArticleen
dc.identifier.journalInt J Cancer 2017; 141(5):905-15en
html.description.abstractNoninvasive biomarkers for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and disease risk stratification are greatly needed. We conducted a nested case-control study within the Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate prediagnostic microRNAs (miRs) as biomarkers of subsequent PDAC risk. A panel of eight miRs (miR-10a, -10b, -21-3p, -21-5p, -30c, -106b, -155 and -212) based on previous evidence from our group was evaluated in 225 microscopically confirmed PDAC cases and 225 controls matched on center, sex, fasting status and age/date/time of blood collection. MiR levels in prediagnostic plasma samples were determined by quantitative RT-PCR. Logistic regression was used to model levels and PDAC risk, adjusting for covariates and to estimate area under the receiver operating characteristic curves (AUC). Plasma miR-10b, -21-5p, -30c and -106b levels were significantly higher in cases diagnosed within 2 years of blood collection compared to matched controls (all p-values <0.04). Based on adjusted logistic regression models, levels for six miRs (miR-10a, -10b, -21-5p, -30c, -155 and -212) overall, and for four miRs (-10a, -10b, -21-5p and -30c) at shorter follow-up time between blood collection and diagnosis (≤5 yr, ≤2 yr), were statistically significantly associated with risk. A score based on the panel showed a linear dose-response trend with risk (p-value = 0.0006). For shorter follow-up (≤5 yr), AUC for the score was 0.73, and for individual miRs ranged from 0.73 (miR-212) to 0.79 (miR-21-5p).


This item appears in the following Collection(s)

Show simple item record